A NEW state-of-the-art cell and gene therapy manufacturing facility in Edinburgh has been formally opened by Ian McCubbin CBE on behalf of Sir Patrick Vallance, the Chief Scientific Adviser to the UK government.
The building which is called the BioCube is an additional home to RoslinCT, one of the worlds leading manufacturers of human cell and gene therapies, which works with clients to develop and manufacture life-changing therapies and cures for patients suffering from some of the most debilitating medical conditions.
Scotland is one of Europes foremost locations for the development ofstem cell technologies andRoslinCTs pioneeringwork and cutting-edgesciencehas been at the forefront of that effort, achieving several global firsts in the field of human cell and gene therapies.
RoslinCT has hired 60 people in the past year and intends to add another 30 full-time employees before the end of 2021, taking headcount to 150 people in order to satisfy demand for its services. The firm has its headquarters at Little France in an area known as the Edinburgh BioQuarter, a leading global destination for healthcare delivery, ground-breaking medical research and life sciences innovation and entrepreneurship.
RoslinCTs new, additional 1,600 square-metre facility includes five clean rooms and a dedicated teaching laboratory that will be home to its Training Academy, where the firms employees and scientists from external organisations will be able to learn and develop their skills and expertise in this important and growing field.
In May 2021, the company was confirmed as one of three National Training Centres within the Advanced Therapies Skills Training Network (ATSTN), a UK government-backed initiative set up by the Cell and Gene Therapy Catapult in collaboration with industry and designed to deliver training in high impact advanced therapy and vaccine manufacturing. RoslinCT will collaborate with the Scottish Universities Life Sciences Alliance (SULSA) and other academic institutions to deliver both theory and practical courses on sterile manufacturing.
Sir Patrick Vallance, Chief Scientific Adviser to the UK Government, said: Cell therapies and genetically-modified cell therapies are huge advances for medicine which are already making a profound difference to the lives of patients, many of them children. The ability to genetically manipulate cells and let them do the work to become the therapy themselves is going to transform medicine in a number of areas and in a number of different ways, providing life-changing opportunities for the treatment of genetic and other disorders.
I couldnt be more excited about the prospect of this new facility and its ability to enhance the potential of the UK as a manufacturing base for these high-tech therapies that will change everything from how we approach cancer treatments to how we deal with rare genetic diseases. The BioCube is an important new part of the overall UK landscape and I offer my congratulations to RoslinCT on this significant step in what is a very important mission.
RoslinCT was established in 2006 as a spin-out from the Roslin Institute, which became famous internationally in 1996 for its pioneering work in cloning Dolly the sheep. RoslinCT is chaired by Ian McCubbin CBE, who has more than 30 years experience of pharmaceutical manufacturing and supply, most recently as a member of the UK governments vaccine taskforce, established in response to the coronavirus in 2020.
Ian McCubbin CBE, Chairman of RoslinCT and a member of the UK Governments Vaccine Taskforce, said: RoslinCThas a proven track-record in hiring many talented scientists to do some of the most ground-breaking manufacturing work in the cell and gene therapies space, pushing the boundaries in this field while developing deep partnerships with clients. That world-class team now has a world-class facility in which it can both work and learn, ensuring we continue to invest in developing our people and their knowledgeandexpertise to the benefit of our clients and, ultimately, patients living with a range of conditions.
RoslinCT is a cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), which means it translates and develops cell and gene therapy research into robust processes which it then progresses to manufacturing. All processes are developed to adhere to Good Manufacturing Practice (GMP), enabling clients to deliver safe therapies to patients. GMP is a globally recognised system designed to ensure pharmaceutical products are created and controlled according to the highest quality standards.
Janet Downie, Chief Executive of RoslinCT, said: It has been my vision to create a world leading CDMO here in Edinburgh and the opening of the BioCube is just the first step in the significant expansion of the already thriving business, both here in Edinburgh and internationally. We have doubled in size within the last 12 months and it is a great pleasure to lead such a talented and inspirational team. I am proud of what we have achieved to date and excited to see the life changing therapies that will be produced from the BioCube in the coming years with our clients, and the positive impact that will have on patients.
Read the original post:
State-of-the-art manufacturing facility opens in Scottish capital - Scottish Business News
- Gene Therapy May Reverse Hurler Syndrome, a Rare and Severe Illness in Kids - HealthDay - November 21st, 2021
- Immunosuppressants linked to severe reactions in people with common genetic profile - Stanford Medical Center Report - November 21st, 2021
- A video that originated on InfoWars is filled with falsehoods about COVID-19 vaccines - PolitiFact - November 21st, 2021
- Gene signature may give an upper hand in metastatic breast cancer - Baylor College of Medicine News - November 21st, 2021
- Lung cancer management in the era of precision medicine - Express Healthcare - November 21st, 2021
- Powerful gene-based testing by integrating long-range chromatin interactions and knockoff genotypes - pnas.org - November 21st, 2021
- Stoke Therapeutics Announces Presentations from the Company's Dravet Syndrome Program at the American Epilepsy Society 2021 Annual Meeting - Business... - November 21st, 2021
- European Commission approves Roche's Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer |... - November 21st, 2021
- Maternal cannabis use is associated with suppression of immune gene networks in placenta and increased anxiety phenotypes in offspring - pnas.org - November 21st, 2021
- Vertex Announces Reimbursement Agreement in Spain for KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With... - November 21st, 2021
- Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled... - November 21st, 2021
- Gene Therapy and Genetic Engineering - MU School of Medicine - November 17th, 2021
- Gene editing: Great for medicine but ethical issues arise - November 17th, 2021
- Gene on, gene off: Chroma Medicine turns lights on with $125M to control gene expression with ex-Editas, Regeneron leaders - FierceBiotech - November 17th, 2021
- gene therapy | Description, Uses, Examples, & Safety ... - November 17th, 2021
- Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development - Yahoo Finance - November 17th, 2021
- CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes -... - November 17th, 2021
- 8 medical advances you may have missed during COVID-19 - AAMC - November 17th, 2021
- PNAS Papers on Woodrat Microbiome, Maternal Cannabis Use, Gene-Based Testing - GenomeWeb - November 17th, 2021
- Single Cell Multiomic Atlas of the Human Retina: An Integrative Analysis - Genetic Engineering & Biotechnology News - November 17th, 2021
- Map of Mouse Iris Offers New Look at the Eye - Howard Hughes Medical Institute - November 17th, 2021
- Is every gene associated with cancer? - Medical News Today - November 15th, 2021
- Years later, a first-of-its-kind treatment shows the power, and limits, of gene therapy - BioPharma Dive - November 15th, 2021
- A mammoth solution - Harvard Office of Technology Development - November 15th, 2021
- Coave Therapeutics Strengthens Leadership Team with the Appointments of Thomas Blaettler MD as Chief Medical Officer and Patricia Franon PhD as Chief... - November 15th, 2021
- Cell and Gene Therapy Catapult and Deep Science Ventures collaborate to overcome barriers in ATMPs - BioPharma-Reporter.com - November 15th, 2021
- Regenerative Medicine Market to reach US$ 25,959.5 Mn by end of 2028, Says Coherent Market Insights - PRNewswire - November 15th, 2021
- Dr Pengyi Yang wins National Stem Cell Foundation Metcalf Prize - News - The University of Sydney - November 15th, 2021
- Researchers make strides identifying genetic causes of rare neurodevelopmental disorders in the Turkish and worldwide populations - Baylor College of... - November 15th, 2021
- Saving the world with synthetic biology - Scope - Scope - November 15th, 2021
- GenSight Biologics to Present New Clinical Data of LUMEVOQ and GS030 Gene Therapies at the American Academy of Ophthalmology 2021 Meeting - Business... - November 15th, 2021
- Gene Therapy ADVM-022 Provides Mixed Efficacy, Safety in Treating DME - MD Magazine - November 15th, 2021
- Role of gene associated with Alzheimer's disease in brain's immune cells investigated by scientists - Devdiscourse - November 15th, 2021
- Attitudes among parents of persons with autism spectrum disorder towards information about genetic risk and future health | European Journal of Human... - November 15th, 2021
- Pierre Fabre and the EspeRare Foundation start the EDELIFE clinical trial of a prenatal treatment for a rare genetic disease, XLHED - PRNewswire - November 15th, 2021
- Arizona researchers have a Valley fever vaccine for dogs and that's good news for humans - KJZZ - November 15th, 2021
- Study revealed the function of mysterious structure found on neurons - Tech Explorist - November 15th, 2021
- New Research Helps Explain the Genetic Basis of Why We Look the Way We Do - UC San Diego Health - November 15th, 2021
- Gene Therapy Shows Early Promise as Angelman Syndrome Treatment | Newsroom - UNC Health and UNC School of Medicine - October 26th, 2021
- Report by Mott Center researchers named NIEHS Extramural Paper of the Month - The South End - October 26th, 2021
- Clinical Data from Editas Medicines Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the European Society of Gene... - October 26th, 2021
- Delic Partners With GT Research for Genetic Analysis of Cannabis, Psychedelic Mushrooms - GenomeWeb - October 26th, 2021
- Alcyone Therapeutics Strengthens Executive Team with New Senior Leadership Appointments - WABI - October 26th, 2021
- The Genomic Revolution: Why Investors Are Paying Attention - Visual Capitalist - October 26th, 2021
- Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007 UltraCAR-T in Advanced ROR1+ Hematological and Solid Tumors - WAGM - October 26th, 2021
- 5 Trends Shaping the Future of eCommerce - Visual Capitalist - October 26th, 2021
- Anatomy texts should show sex as a spectrum to include intersex people - The Conversation AU - October 26th, 2021
- Early Results of Gene Therapy for Angelman Syndrome Look Promising - AJMC.com Managed Markets Network - October 24th, 2021
- Ten Years On, Gene Therapy Still Beating Most Cases of 'Bubble Boy' Immune Disease - HealthDay News - October 24th, 2021
- Graphite Bio Announces Participation in Upcoming Jefferies Gene Therapy/Editing Summit - Yahoo Finance - October 24th, 2021
- Generation Bio Presents Data Demonstrating First Lipid Nanoparticle to Achieve Uniform Retinal Transduction and Tolerability via Sub-Retinal Delivery... - October 24th, 2021
- ViaCyte to Present at the Jefferies Gene Therapy/Editing Summit - WCAX - October 24th, 2021
- Lovelace Biomedical Presents a New Webinar on Rare Diseases and Gene Therapy Preclinical Research - PRNewswire - October 24th, 2021
- Novartis has negotiated Zolgensma access for half of the European SMA population, exec says. How'd it get there? - FiercePharma - October 24th, 2021
- Senti Bio CEO Appointed to The Alliance for Regenerative Medicine 2022 Board of Directors - StreetInsider.com - October 24th, 2021
- ReCode Therapeutics gets $80M to deliver on new RNA therapies for the lungs - MedCity News - October 24th, 2021
- From cancer to Crohn, Israel pushes precision medicine to the next level - The Jerusalem Post - October 24th, 2021
- Tulane scientists unravel 50-year-old medical mystery behind toddlers' deaths from RSV vaccine - Tulane News - October 24th, 2021
- Dr. Helen Heslop elected to the National Academy of Medicine - Baylor College of Medicine News - October 24th, 2021
- Boehringer Acquires Rights to Potential CF Inhalation Gene Therapy - Cystic Fibrosis News Today - October 24th, 2021
- LogicBio Therapeutics Announces Successful Repopulation of Diseased Livers in Mice with Healthy Corrected Hepatocytes in Two New Indications Using... - October 24th, 2021
- Global Pharmaceutical Contract Development and Manufacturing Markets, 2021-2026 - Increasing Demand for Biological & Cell and Gene Therapies /... - October 24th, 2021
- Precision medicine data dive shows water pill may be viable to test as Alzheimer's treatment - The Highland County Press - October 24th, 2021
- Hunterian Medicine Licenses Inscriptas MAD7 Nuclease to Advance Gene Editing Research and Development - Yahoo Finance - October 17th, 2021
- Precision medicine data dive shows water pill may be viable to test as Alzheimer's treatment - National Institutes of Health - October 17th, 2021
- 4 Biotechs to Watch Amid Rising Prominence of Gene Therapies - Yahoo Finance - October 17th, 2021
- The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics - Yahoo Finance - October 17th, 2021
- Could an Old Drug Be a New Alzheimers Treatment? - AARP - October 17th, 2021
- 5 Slides: Gene therapy and the promise for rare disease - State of Reform - State of Reform - October 17th, 2021
- Harvard's R&D alliance with Resilience to advance manufacture of complex medicines - Harvard Gazette - October 17th, 2021
- Generation Bio to Present at European Society of Gene and Cell Therapy 2021 Annual Virtual Congress - StreetInsider.com - October 17th, 2021
- Genetic screening test leads to discovery of a family trait - Sanford Health News - October 17th, 2021
- Filling the gaps: connecting genes to diseases through proteins - EurekAlert - October 17th, 2021
- Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development - GlobeNewswire - October 17th, 2021
- Polygenic screening of embryos is here, but is it ethical? - The Guardian - October 17th, 2021
- Wolter Earns Young Investigator Award | Newsroom - UNC Health and UNC School of Medicine - October 17th, 2021
- Patient Care on the Precipice of Transformation at Penn Medicine's New Pavilion - pennmedicine.org - October 17th, 2021
- ViaCyte to Present at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa - PRNewswire - October 11th, 2021
- CRISPR is revolutionizing medicine its origin story is pretty incredible, too - Freethink - October 11th, 2021
- Longevity Foundation to Fund Geroscience Research with 860M - Labiotech.eu - October 11th, 2021